Opendata, web and dolomites

ERA4TB SIGNED

EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ERA4TB project word cloud

Explore the words cloud of the ERA4TB project. It provides you a very rough idea of what is the project "ERA4TB" about.

unavailable    models    nir    tb    extensive    assays    2030    murine    treat    compounds    aids    fiber    bioavailable    imaging    artificial    outcome    comprising    ready    safe    trials    diabetes    discovery    predict    ct    forms    orally    treatment    monitor    innovative    invasive    era4tb    combination    cell    human    expertise    progress    tests    evaluation    preclinical    therapy    profiling    formulation    pd    starting    ending    negligible    pharmacological    details    progression    vitro    shortening    hiv    leads    drugs    accelerator    hollow    regimens    strategy    execute    sustainable    biomarker    interactions    simulation    drug    single    explicit    tools    comorbidities    assembled    combined    pet    disease    dynamic    agile    regimen    ranking    enter    decision    combinations    tolerated    clinical    intelligence    exposure    un    portfolio    tuberculosis    molecules    compatible    pk    flexible    algorithm    construction    efpia    characterisation    bactericidal    primate    time    first    candidates    constitute    aided    doses    active    entails    20    series    points   

Project "ERA4TB" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD CARLOS III DE MADRID 

Organization address
address: CALLE MADRID 126
city: GETAFE (MADRID)
postcode: 28903
website: http://www.uc3m.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 207˙963˙991 €
 EC max contribution 89˙815˙600 € (43%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2018-15-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2025-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD CARLOS III DE MADRID ES (GETAFE (MADRID)) coordinator 5˙804˙800.00
2    FONDATION INNOVATIVE MEDICINES FOR TUBERCULOSIS (IM4TB) CH (LAUSANNE) participant 22˙407˙250.00
3    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 16˙997˙500.00
4    INSTITUT PASTEUR FR (PARIS CEDEX 15) participant 12˙003˙900.00
5    UNIVERSIDAD DE ZARAGOZA ES (ZARAGOZA) participant 4˙247˙900.00
6    CRITICAL PATH INSTITUTE, LIMITED IE (DUBLIN) participant 3˙557˙500.00
7    INSTITUT PASTEUR DE LILLE FONDATION FR (LILLE) participant 2˙853˙750.00
8    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 2˙443˙750.00
9    FORSCHUNGSZENTRUM BORSTEL DE (BORSTEL) participant 2˙287˙500.00
10    COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES FR (PARIS 15) participant 2˙012˙500.00
11    BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE FR (LYON) participant 1˙856˙250.00
12    UPPSALA UNIVERSITET SE (UPPSALA) participant 1˙797˙500.00
13    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 1˙677˙500.00
14    SCIENSANO BE (ELSENE) participant 1˙637˙500.00
15    Department of Health UK (Leeds) participant 1˙557˙500.00
16    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 1˙407˙500.00
17    GRITSYSTEMS AS DK (VALBY) participant 1˙132˙500.00
18    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 962˙500.00
19    IMABIOTECH SAS FR (LOOS) participant 837˙500.00
20    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 615˙000.00
21    UNIVERSITA DEGLI STUDI DI PAVIA IT (PAVIA) participant 592˙000.00
22    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 293˙500.00
23    LATVIJAS ORGANISKAS SINTEZES INSTITUTS LV (RIGA) participant 277˙500.00
24    LUNDS UNIVERSITET SE (LUND) participant 277˙500.00
25    QPS NETHERLANDS BV NL (GRONINGEN) participant 277˙500.00
26    BILL & MELINDA GATES FOUNDATION US (SEATTLE, WASHINGTON) participant 0.00
27    EVOTEC INTERNATIONAL GMBH DE (HAMBURG) participant 0.00
28    GLAXOSMITHKLINE INVESTIGACION Y DESARROLLO SL ES (TRES CANTOS) participant 0.00
29    GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT NON PROFIT ORGANISATION US (NEW YORK) participant 0.00
30    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
31    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 0.00

Map

 Project objective

The European Regimen Accelerator for Tuberculosis (ERA4TB) has the explicit goal of developing a new combination therapy to treat all forms of TB starting from ~20 leads and drug candidates provided by EFPIA. Since details of these are as yet unavailable, we will implement an agile drug development algorithm that entails profiling and portfolio construction. Profiling involves characterisation and ranking molecules in preclinical studies comprising in vitro drug combination assays, hollow fiber and single cell analysis, innovative murine and non-human primate models, PK/PD studies, combined with biomarker discovery and non-invasive NIR or PET/CT imaging to monitor disease progression and response to treatment. Modelling, simulation and artificial intelligence tools will help progress compounds from early preclinical to clinical development and to predict drug exposure, human doses and the best combinations. After extensive preclinical profiling, selected compounds will enter portfolio development for first time in human tests and phase I clinical trials in order to ensure that they are safe, well-tolerated and bioavailable with negligible drug-drug interactions. If needed, formulation studies will be conducted to improve pharmacological properties. ERA4TB has assembled the best expertise and resources available in Europe, to build a highly effective and sustainable drug development consortium with a flexible and dynamic management system to execute the profiling and portfolio strategy, aided by clearly defined go/no-go decision points. The expected outcome of ERA4TB is a series of highly active, bactericidal, orally available drugs to constitute two or more new combination regimens with treatment-shortening potential ready for Phase II clinical evaluation. These regimens will be compatible with drugs used to treat common comorbidities, such as HIV-AIDS and diabetes, and should impact UN Sustainable Development Goal 3, namely, ending TB by 2030.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ERA4TB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ERA4TB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

VITAL (2019)

Vaccines and Infectious Diseases in the Ageing PopuLation

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More  

WEB-RADR 2 (2018)

WEB-RADR 2

Read More